News

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome
Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone ...
The Manila Times6d
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
QRX003 is being well tolerated by the patient and no adverse events have been reported. As a result of these positive initial ...